Oral Anticoagulant Therapy in Patients with Coronary Artery Disease

Daniel G. Hackam; Sonia S. Anand; Salim Yusuf

doi:10.1055/s-2003-44468

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2003; 03(3): 323-332
DOI: 10.1055/s-2003-44468

Oral Anticoagulant Therapy in Patients with Coronary Artery Disease

Daniel G. Hackam¹ , Sonia S. Anand^1,2,3 , Salim Yusuf^1,2,3

¹Department of MedicineMcMaster University, Hamilton, Ontario, Canada
²Division of Cardiology, McMaster University, Hamilton, Ontario, Canada
³Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada

Abstract

ABSTRACT

Oral anticoagulation (OA) has been used to treat patients with coronary artery disease (CAD) for more than 40 years and has been a subject of intense controversy since that time. Seven to 10% of patients with acute myocardial infarction (MI) develop recurrent MI, stroke, or death in the 6 weeks following the index event and approximately 20% after 4 years, despite optimal background therapy with aspirin. Recent large studies and systematic reviews have greatly clarified the role of OA in the modern era. On the weight of the evidence, which is reviewed in detail in this article, long-term, moderate-intensity OA (International Normalized Ratio 2.0 to 3.0) should be considered an option for the prevention of recurrent CAD, particularly in high-risk patients.

KEYWORDS

Oral anticoagulants - coronary artery disease - prevention

Full Text

References

REFERENCES

1 Anand S S, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA . 1999; 282 2058-2067
2 Oasis Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol . 2001; 37 475-484
3 Fiore L D, Ezekowitz M D, Brophy M T, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation . 2002; 105 557-563
4 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med . 2002; 347 969-974
5 Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation . 2001; 103 3069-3074
6 ten Berg M J, Kelder J C, Suttorp M J. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. Circulation . 2000; 102 386-391
7 van Es F R, Jonker J J, Verheugt F W, Deckers J W, Grobbee D E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet . 2002; 360 109-113
8 Brouwer M A, Verheugt F WA. Oral anticoagulation for acute coronary syndromes. Circulation . 2002; 105 1270-1274
9 Bahit M C, Granger C B, Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. Am Heart J . 2002; 143 205-216
10 Corti R, Farkouh M E, Badimon J J. The vulnerable plaque and acute coronary syndromes. Am J Med . 2002; 113 668-680
11 Merlini P A, Bauer K A, Oltrona L. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation . 1994; 90 61-68
12 Becker R C. Antithrombotic therapy after myocardial infarction [editorial]. N Engl J Med . 2002; 347 1019-1022
13 Awtry E H, Loscalzo J. Aspirin. Circulation . 2000; 101 1206-1218
14 Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J . 2002; 324 71-86
15 Yusuf S, Zhao F, Mehta S R, Chrolavicius S, Tognoni G, Fox K K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med . 2001; 345 494-502
16 Cairns J A, Theroux P, Lewis Jr D H, Ezekowitz M, Meade T W. Antithrombotic agents in coronary artery disease. Chest . 2001; 119 228S-252S
17 Hirsh J, Dalen J, Anderson D R. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest . 2001; 119 8S-21S
18 Aspect Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet . 1994; 343 499-503
19 Loeliger E A, Hensen A, Kroes F. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand . 1967; 182 549-566
20 Lovell R R, Denborough M A, Nestel P J, Goble A J. A controlled trial of long-term treatment with anticoagulants after myocardial infarction in 412 male patients. Med J Aust . 1967; 2 97-104
21 Seaman A J, Griswold H E, Reaume R B, Ritzmann L. Long-term anticoagulant prophylaxis after myocardial infarction. N Engl J Med . 1969; 281 115-119
22 Sorensen O H, Friis T, Jorgensen A W, Jorgensen M B, Nissen N I. Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand . 1969; 185 65-72
23 A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet . 1980; 2 989-994
24 Meuwissen O J, Vervoorn A C, Cohen O, Jordan F L, Nelemans F A. Double blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand . 1969; 186 361-368
25 Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation . 1980; 62 V63-V72
26 Apenstrom G, Korsan-Bengtsen K. A double blind study of dicumarol prophylaxis in coronary heart disease. Acta Med Scand . 1964; 176 563-575
27 Borchgrevink C F. Long-term anticoagulant therapy in angina pectoris and myocardial infarction. Acta Med Scand Suppl . 1960; 359
28 Conrad L L, Kyriacopoulous J D, Honick G L. Prevention of recurrences of myocardial infarction. Arch Intern Med . 1964; 114 348-358
29 Harvald B, Hilden T, Letman H, Lund E, Thaysen E H, Worning H. Long-term anticoagulant treatment in myocardial infarction. Acta Med Scand . 1961; 21 983-987
30 Clausen J, Andersen P E, Andresen P. Studies on long-term anticoagulant treatment after coronary occlusion. Acta Med Scand . 1961; 123 987-994
31 McEnany M T, Salzman E W, Mundth E D. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg . 1982; 83 81-89
32 Williams D O, Kirby M G, McPherson K, Phear D N. Anticoagulant treatment of unstable angina. Br J Clin Pract . 1986; 40 114-116
33 Ebert R V. Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration cooperative study. JAMA . 1969; 207 2263-2267
34 A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med . 1982; 307 701-708
35 Medical Research Council Working Party. An assessment of long-term anticoagulant administration after cardiac infarction. Br Med J . 1964; 2 837-843
36 Kraska T, Malanowicz W, Skarzynska M, Tyminska K. [Results of prevention of second myocardial infarct with syncumar or aspirin]. Kardiol Pol . 1981; 24 593-597
37 Eritsland J, Arnesen H, Gronseth K, Fjeld N B, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol . 1996; 77 31-36
38 van der J M, Hillege H L, Kootstra G J. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Lancet . 1993; 342 257-264
39 Cohen M, Adams P C, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol . 1990; 66 1287-1292
40 Anand S S, Yusuf S, Pogue J, Weitz J I, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation . 1998; 98 1064-1070
41 Cohen M, Adams P C, Parry G. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation . 1994; 89 81-88
42 Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet . 1997; 350 389-396
43 Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med . 1997; 336 153-162
44 Massel D, Little S H. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol . 2001; 37 569-578
45 Verheugt F W. Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease. J Cardiovasc Risk . 1996; 3 229-232
46 Verheugt F W, Gersh B J. Aspirin beyond platelet inhibition. Am J Cardiol . 2002; 90 39-41
47 Steinhubl S R, Berger P B, Mann III T J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA . 2002; 288 2411-2420
48 Mehta S R, Yusuf S, Peters R J. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet . 2001; 358 527-533
49 Eriksson B I, Bergqvist D, Kalebo P. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet . 2002; 360 1441-1447
50 Francis C W, Davidson B L, Berkowitz S D. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med . 2002; 137 648-655
51 Gum P A, Kottke-Marchant K, Poggio E D. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol . 2001; 88 230-235
52 McKee S A, Sane D C, Deliargyris E N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost . 2002; 88 711-715
53 Eikelboom J W, Hirsh J, Weitz J I, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation . 2002; 105 1650-1655